{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-014265","form_type":"8-K","ticker":"CPIX","cik":"0001087294","company_name":"CUMBERLAND PHARMACEUTICALS INC","filed_at":"2023-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.900500+00:00","generated_at":"2026-06-16T06:09:17.868753+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Cumberland shareholders elect directors, ratify auditor, approve say-on-pay and incentive plan amendment","bullets":["Class I directors Krogulski (99.1%) and Young (90.7%) elected; Class II director Brown (98.6%) elected.","Ratification of FORVIS as auditor for 2023 received 99.1% votes in favor.","Advisory say-on-pay resolution approved with 89.9% votes in favor.","Amendment to 2007 Long-Term Incentive Plan approved with 75.0% votes in favor."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-014265","json":"https://secwatch.observer/filing/0001628280-23-014265.json","markdown":"https://secwatch.observer/filing/0001628280-23-014265.md","text":"https://secwatch.observer/filing/0001628280-23-014265.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1087294/000162828023014265/0001628280-23-014265-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1087294/000162828023014265/cpix-20230425.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T06:09:17.868753+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"14ec5ad82c2097c5be559b9d4e34f0060f366946","claim":"CUMBERLAND PHARMACEUTICALS INC shareholders approved Approval of an amendment to the Amended and Restated 2007 Long-Term Incentive Compensation Plan at the 2023-04-25 meeting.","evidence_excerpt":"Approve an amendment to the amended and restated 2007 long-term incentive compensation plan 6,869,796 2,286,706 — 26,353 75.0%","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1087294/000162828023014265/0001628280-23-014265-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-04-25"}],"fact_type":"shareholder_vote"},{"claim_id":"ac53b4174e85555107b262d4978b7d9413d52f6b","claim":"CUMBERLAND PHARMACEUTICALS INC shareholders approved Resolution regarding compensation of the named executive officers at the 2023-04-25 meeting.","evidence_excerpt":"Resolution regarding compensation of named officers 8,228,888 926,046 — 27,921 89.9%","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1087294/000162828023014265/0001628280-23-014265-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-04-25"}],"fact_type":"shareholder_vote"},{"claim_id":"ad67a0fbdba219b05a99c69a9ba7ac8daf2ee263","claim":"CUMBERLAND PHARMACEUTICALS INC shareholders approved Ratification of the appointment of FORVIS, LLP as independent registered public accounting firm for the year ending December 31, 2023 at the 2023-04-25 meeting.","evidence_excerpt":"Appointment of FORVIS, LLP as our independent registered public accounting firm for the year ending December 31, 2023 11,474,731 107,830 — 17,830 99.1%","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1087294/000162828023014265/0001628280-23-014265-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-04-25"}],"fact_type":"shareholder_vote"},{"claim_id":"f674a5f30135ec2ceddda5c3f3cbf4e82a9b17bc","claim":"CUMBERLAND PHARMACEUTICALS INC shareholders approved Election of Directors at the 2023-04-25 meeting.","evidence_excerpt":"The voting results were as follows: For Against Withheld Abstentions % of Votes in Favor Kenneth J. Krogulski 9,100,390 — 82,465 — 99.1% Caroline R. Young 8,326,006 — 856,849 — 90.7% Martin S. Brown, Jr. 9,053,642 — 129,213 — 98.6%","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1087294/000162828023014265/0001628280-23-014265-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-04-25"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}